89510-90-7

Basic information

• Product Name: 4-amino-2-chloro-5-fluoropyridine
• Synonyms: 4-amino-2-chloro-5-fluoropyridine;2-Chloro-5-fluoro-4-pyridinaMine;4-PyridinaMine, 2-chloro-5-fluoro-
• CAS NO: 89510-90-7
• Molecular Formula: C₅H₄ClFN₂
• Molecular Weight: 146.5500632
• Mol File: 89510-90-7.mol
• Article Data: 7

Chemical Properties

• Melting Point: 110-111 °C(Solv: water (7732-18-5))
• Boiling Point: 266.982ºC at 760 mmHg
• Flash Point: 115.267ºC
• Appearance: /
• Density: 1.45g/cm3
• Vapor Pressure: 0.008mmHg at 25°C
• Refractive Index: 1.576
• Storage Temp.: Keep in dark place,Inert atmosphere,Room temperature
• PKA: 2.81±0.42(Predicted)
• CAS DataBase Reference: 4-amino-2-chloro-5-fluoropyridine(CAS DataBase Reference)
• NIST Chemistry Reference: 4-amino-2-chloro-5-fluoropyridine(89510-90-7)
• EPA Substance Registry System: 4-amino-2-chloro-5-fluoropyridine(89510-90-7)

Safety Data

• Hazardous Substances Data: 89510-90-7(Hazardous Substances Data)

Usage

General Description

4-amino-2-chloro-5-fluoropyridine is a chemical compound with the molecular formula C5H4ClFN2. It is a pyridine derivative with a chlorine atom at the 2-position and a fluorine atom at the 5-position. It is commonly used as an intermediate in the synthesis of pharmaceuticals and agrochemicals. The compound has potential applications in the field of medicinal chemistry and drug development due to its ability to serve as a building block for the synthesis of various biologically active molecules. Additionally, it is also used in the production of dyes and other organic compounds. The compound is known for its moderate solubility in water and its relatively high stability under normal conditions.

InChI:InChI=1/C5H4ClFN2/c6-5-1-4(8)3(7)2-9-5/h1-2H,(H2,8,9)

Upstream product

• 31301-51-6 2-chloro-5-fluoropyridine 
• 884494-49-9 2-chloro-5-fluoro-4-iodopyridine 
• 1354223-67-8 tert-butyl (2-chloro-5-fluoropyridin-4-yl)carbamate 
• 405230-79-7 2-chloro-5-fluoropyridine-1-oxide 
• 405230-80-0 2-chloro-5-fluoro-4-nitropyridine-1-oxide 

Downstream Products

• 202806-40-4 3-deaza-3-fluoro-adenosine 
• 405230-97-9 4-chloro-7-fluoro-1H-imidazo[4,5-c]pyridine 
• 405230-93-5 2-chloro-3,4-diamino-5-fluoropyridine 
• 405230-90-2 4-amino-2-chloro-5-fluoro-3-nitropyridine 
• 405231-08-5 4-chloro-7-fluoro-1-(2,3,5-tri-O-benzoyl-β-D-ribofuranosyl)imidazo[4,5-c]pyridine 
• 1354223-67-8 tert-butyl (2-chloro-5-fluoropyridin-4-yl)carbamate 
• 1334411-83-4 4-bromo-2-(2,6-dichlorophenyl)-7-fluoro-1H-imidazo[4,5-c]pyridine 
• 1334411-84-5 4-chloro-7-fluoro-2-(2,6-dichlorophenyl)-1H-imidazo[4,5-c]pyridine 
• 1334407-23-6 N-(2-(2,6-dichlorophenyl)-7-fluoro-1H-imidazo[4,5-c]pyridin-4-yl)cyclopropanecarboxamide 
• 1334407-22-5 2-(2,6-dichlorophenyl)-N-(2,6-dimethylpyrimidin-4-yl)-7-fluoro-1H-imidazo[4,5-c]pyridin-4-amine 
• 405230-86-6 2-chloro-5-fluoro-4-nitraminopyridine 

Relevant articles and documents

Design, synthesis and biological evaluation of novel substituted purine isosters as EGFR kinase inhibitors, with promising pharmacokinetic profile and in vivo efficacy

Novel substituted purine isosters, were designed and synthesized as potential inhibitors of the Epidermal Growth Factor Receptor (EGFR). The compounds were rationally designed through bioisosteric replacement of the central quinazoline core of lapatinib, an approved drug that inhibits both EGFR and HER2, another important member of this family of receptors. The new target molecules were evaluated as inhibitors of receptor phosphorylation at the cellular level, for their direct inhibitory action on the intracellular receptor kinase domain and for their cytotoxicity against the non-small cell lung cancer cell line A549 and breast cancer HCC1954, cell lines which are associated with overexpression of EGFR and HER2, respectively. The most potent derivatives were further studied for their cellular uptake levels and in vivo pharmacokinetic properties. One compound (23)displayed a noteworthy pharmacokinetic profile, and higher intracellular accumulation in comparison to lapatinib in the A549 cells, possibly due to its higher lipophilicity. This lead compound (23)was assessed for its efficacy in an EGFR positive xenograft model, where it successfully inhibited tumor growth, with a similar efficacy with that of lapatinib and with minimal phenotypic toxicity.

NOVEL NICOTINAMIDE DERIVATIVES OR SALTS THEREOF

An object of the present invention is to provide to a compound and a pharmaceutical composition, which have excellent Syk-inhibitory activity. Th e present invention provides a nicotinamide derivative represented by the follo wing formula (I) (wherein R 1 represents a halogen atom; R 2 represents a C 1-12 alkyl group, a C 2-12 alkenyl group, a C 2-12 alkynyl group, a C 3-8 cycloalkyl g roup, an aryl group, an ar-C 1-6 alkyl group or a heterocyclic group, each opti onally having at least one substituent; R 3 represents an aryl group or a hetero cyclic group each optionally having at least one substituent; and R 4 and R 5 e ach independently represent a hydrogen atom; and R 2 and R 4 may form a cyc lic amino group optionally having at least one substituent together with the ni trogen atom to which they bind) or a salt thereof, and a pharmaceutical comp osition for use in the treatment of a Syk-related disease which comprises the nicotinamide derivative or a salt thereof.

IMIDAZOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE

The invention provides compounds of Formulas Ia-Ib, stereoisomers or pharmaceutically acceptable salts thereof, wherein A, X, R1, R2, R4, R5 and R16 are defined herein, a pharmaceutical composition that includes a compound of Formulas Ia-Ib and a pharmaceutically acceptable carrier, adjuvant or vehicle, and methods of using the compound or composition in therapy.